James Kasinger Sells 3,182 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 3,182 shares of CRISPR Therapeutics stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $46.78, for a total transaction of $148,853.96. Following the sale, the general counsel directly owned 94,308 shares of the company’s stock, valued at $4,411,728.24. This represents a 3.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

CRISPR Therapeutics Stock Up 1.0%

CRSP stock opened at $47.55 on Friday. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48. The company has a market cap of $4.56 billion, a P/E ratio of -7.29 and a beta of 1.72. The business’s fifty day moving average is $52.57 and its 200-day moving average is $56.89.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $4.72 million. During the same period last year, the firm earned ($1.01) earnings per share. The firm’s revenue for the quarter was down 97.8% on a year-over-year basis. Research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

Large investors have recently added to or reduced their stakes in the company. Mcguire Capital Advisors Inc. acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $25,000. Ramirez Asset Management Inc. acquired a new position in shares of CRISPR Therapeutics during the fourth quarter worth about $26,000. Optiver Holding B.V. boosted its position in shares of CRISPR Therapeutics by 71.4% during the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after buying an additional 210 shares during the period. Thompson Investment Management Inc. bought a new position in shares of CRISPR Therapeutics during the third quarter worth about $33,000. Finally, Strategic Advocates LLC acquired a new stake in CRISPR Therapeutics in the 3rd quarter valued at approximately $34,000. Institutional investors own 69.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on CRSP shares. Needham & Company LLC increased their price target on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, February 13th. Evercore restated an “outperform” rating and set a $74.00 price objective on shares of CRISPR Therapeutics in a report on Friday, February 13th. Chardan Capital upped their target price on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research note on Saturday, February 14th. Citizens Jmp reduced their price target on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research report on Friday, January 30th. Finally, TD Cowen boosted their price target on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $64.53.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.